GnRHa/Stanozolol Combined Therapy Maintains Normal Bone Growth in Central Precocious Puberty

BACKGROUND: Gonadotropin-releasing hormone agonist (GnRHa) is the gold standard in the treatment of Central Precocious Puberty (CPP) with progressive puberty and accelerative growth. However, GnRHa treatment is reported to result in growth deceleration and prevents growth plate development which lea...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Front Endocrinol (Lausanne)
Egile Nagusiak: Zhu, Shunye, Long, Lingli, Hu, Yue, Tuo, Ying, Li, Yubin, Yu, Zhenhua
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Frontiers Media S.A. 2021
Gaiak:
Endocrinology
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8221533/
https://ncbi.nlm.nih.gov/pubmed/34177807
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fendo.2021.678797
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak